Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Next Previous
Trial Profile

A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bersacapavir (Primary) ; JNJ 73763989 (Primary) ; Entecavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms REEF-1
  • Sponsors Janssen Pharmaceutical KK; Janssen Sciences Ireland UC

Most Recent Events

  • 01 Oct 2023 According to Janssen Pharmaceuticals media release, Janssen Pharmaceuticals has changed its name to Johnson & Johnson Innovative Medicine.
  • 24 Jun 2023 Results using data from the global phase 2b REEF-1 and REEF-2 trials , assessing self-stigma in people with CHB using content and psychometric validation of a new patient-reported outcome instrument, presented at the European Association for the Study of the Liver Congress 2023
  • 08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top